Alerts will be sent to your verified email
Verify Email
NORRIS
|
Norris Medicines
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
47.03 % | 13.7 % | -1624.87 % |
|
5yr average Equity Multiplier
|
-2.46 | 1.24 | 46.04 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.36 | 0.95 |
|
5yr Avg Net Profit Margin
|
-30.66 % | 71.53 % | -9.48 % |
|
Price to Book
|
0.0 | 2.21 | 0.0 |
|
P/E
|
0.0 | 53.57 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
97.28 Days | 68.18 Days | -161.05 Days |
|
Inventory Days
|
165.43 Days | 62.21 Days | 73.65 Days |
|
Days Receivable
|
69.98 Days | 10.88 Days | 40.27 Days |
|
Days Payable
|
260.51 Days | 199.95 Days | 328.05 Days |
|
5yr Average Interest Coverage Ratio
|
-1.37 | 815.2 | 1.16 |
|
5yr Avg ROCE
|
-19.87 % | 19.97 % | -9.94 % |
|
5yr Avg Operating Profit Margin
|
-6.94 % | -101.39 % | 3.93 % |
|
5 yr average Debt to Equity
|
-3.0 | 0.0 | 17.42 |
|
5yr CAGR Net Profit
|
-15.97 % | 0.0 | n/a |
|
5yr Average Return on Assets
|
-18.92 % | 10.86 % | -6.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.0 % | 59.53 % | 30.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.04 % | 1.02 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Norris Medicines
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|